ACRS
NASDAQAclaris Therapeutics Inc.
Price$4.34+1.23 (+39.42%)
2026-03-052026-06-08
News · 26 weeks55-85%
2025-12-142026-06-07
Mix2490d
- SEC Filings8(33%)
- Other8(33%)
- Earnings3(13%)
- Analyst2(8%)
- Insider2(8%)
- Leadership1(4%)
Latest news
25 items- SECAclaris Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Aclaris Therapeutics, Inc. (0001557746) (Filer)
- PRAclaris Therapeutics to Participate in the 2026 Jefferies Global Healthcare ConferenceWAYNE, Pa., May 28, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that on Thursday June 4, 2026, at 2:00 PM ET, Aclaris' Chief Executive Officer Dr. Neal Walker and other members of Aclaris' senior leadership team will participate in a fireside chat during the 2026 Jefferies Global Healthcare Conference in New York, NY. A live and archived webcast of this event will be accessible on the Events page of the Aclaris website, www.aclaristx.com. The webcast will be available on the Aclaris website for at least 30 days. About Aclaris T
- PRAclaris Therapeutics to Participate in the 2026 Bank of America Healthcare ConferenceWAYNE, Pa., May 08, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that on Thursday May 14, 2026, at 9:35 AM PT, Aclaris' President and Chief Operating Officer Dr. Hugh Davis will provide a corporate presentation during the 2026 Bank of America Healthcare Conference in Las Vegas, NV. A live and archived webcast of this event will be accessible on the Events page of the Aclaris website, www.aclaristx.com. The webcast will be available on the Aclaris website for at least 30 days. About Aclaris Therapeutics, Inc. Aclaris Therapeutic
- SECSEC Form 10-Q filed by Aclaris Therapeutics Inc.10-Q - Aclaris Therapeutics, Inc. (0001557746) (Filer)
- SECAclaris Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Aclaris Therapeutics, Inc. (0001557746) (Filer)
- PRAclaris Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate and Clinical Update- Full Top Line Results from Phase 1a SAD/MAD Trial of ATI-052 Exceed Aclaris' Target Profile, Validating Potential Best-in-Class Potency Advantage and Opportunity for Extended Dosing - - Unique Dual Mechanism of ATI-2138 Supports Planned Phase 2b Clinical Trial in Lichen Planus - - Strong Cash Runway Expected to Enable Development of Pipeline Through 2028 - WAYNE, Pa., May 07, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced its financial results for the first quarter of 2026 and provided a corporate and clinical update. "Since t
- INSIDERChief Medical Officer Hall Jesse Wayne converted options into 36,375 shares and covered exercise/tax liability with 9,330 shares (SEC Form 4) to satisfy withholding tax4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)
- ANALYSTGuggenheim initiated coverage on Aclaris Therapeutics with a new price targetGuggenheim initiated coverage of Aclaris Therapeutics with a rating of Buy and set a new price target of $12.00
- SECAclaris Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Aclaris Therapeutics, Inc. (0001557746) (Filer)
- PRAclaris Therapeutics Announces Positive Full Top Line First-in-Human Results from Phase 1a Healthy Volunteer Clinical Trial of ATI-052, a Novel Potential First-in-Class Anti-TSLP/IL-4Rα Bispecific Antibody, and Announces Lichen Planus as Lead Indication for ATI-2138, an Oral ITK/JAK3 Inhibitor- Positive Full Results from Phase 1a Trial of Anti-TSLP/IL-4Rα Bispecific Antibody ATI-052 Exceed Aclaris' Target Profile, Validating Potential Best-in-Class Potency Advantage and Opportunity for Extended Dosing - - Estimated Half-Life of Approximately 45 Days; Unlocks Opportunity for up to Three-Month Dosing Interval - - Complete and Sustained Inhibition of TSLP-Induced and IL-4 Induced CCL17 (TARC) Provides Potential to Raise Efficacy Ceiling in Th2-Driven Diseases - - Enrollment and Dosing Ongoing in Phase 1b Trials in Asthma and Atopic Dermatitis (AD) with Top Line Results Expected in the Second Half of 2026 - - Lichen Planus Selected as Lead Indication for ATI-2138; Potential to b
- INSIDERLarge owner Leonard Braden Michael sold $1,359,000 worth of shares (300,000 units at $4.53) (SEC Form 4)4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Aclaris Therapeutics Inc.SCHEDULE 13G/A - Aclaris Therapeutics, Inc. (0001557746) (Subject)
- PRAclaris Therapeutics to Provide Clinical Update on Key Biologic and Oral Inhibitor Programs on April 28, 2026WAYNE, Pa., April 27, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that it will provide the full results from its Phase 1a single and multiple ascending dose trial of its anti-TSLP/IL-4R bispecific antibody ATI-052 and the results of its lead indication selection process for its ITK/JAK3 Inhibitor ATI-2138 before the opening of the financial markets tomorrow, April 28, 2026. Aclaris will host a webcast and conference call with slides tomorrow morning at 8:30 AM EST to discuss these updates. The live and archived webcast will be a
- SECSEC Form DEFA14A filed by Aclaris Therapeutics Inc.DEFA14A - Aclaris Therapeutics, Inc. (0001557746) (Filer)
- SECSEC Form DEF 14A filed by Aclaris Therapeutics Inc.DEF 14A - Aclaris Therapeutics, Inc. (0001557746) (Filer)
- ANALYSTOppenheimer initiated coverage on Aclaris Therapeutics with a new price targetOppenheimer initiated coverage of Aclaris Therapeutics with a rating of Outperform and set a new price target of $10.00
- PRAclaris Therapeutics to Participate in the H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual ConferenceWAYNE, Pa., April 08, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that on Tuesday, April 14, 2026, at 12:00 PM EDT, Aclaris' Chief Executive Officer Dr. Neal Walker and other members of Aclaris' senior leadership team will participate in a fireside chat during the H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference. A live and archived webcast of this event will be accessible on the Events page of the Aclaris website, www.aclaristx.com. The webcast will be available on the Aclaris website for at least 30 days
- SECSEC Form SCHEDULE 13G filed by Aclaris Therapeutics Inc.SCHEDULE 13G - Aclaris Therapeutics, Inc. (0001557746) (Subject)
- PRResults Presented at 2026 American Academy of Dermatology (AAD) Annual Meeting Provide Additional Support for the Therapeutic Potential of ATI-2138- Participants with Atopic Dermatitis Receiving ATI-2138 Experienced Improvements in Key Clinical Measures including Disease Severity, Itch, and Quality of Life - WAYNE, Pa., March 27, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today provided additional results from its Phase 2a trial of ATI-2138, a potent and selective investigational oral covalent inhibitor of ITK and Janus kinase 3 (JAK3), presented in an electronic poster at the 2026 American Academy of Dermatology (AAD) Annual Meeting in Denver, CO. "We have continued to achieve importan
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Aclaris Therapeutics Inc.SCHEDULE 13G/A - Aclaris Therapeutics, Inc. (0001557746) (Subject)
- PRAclaris Therapeutics Announces Poster on Results from Phase 2a Trial of ATI-2138 at the 2026 American Academy of Dermatology (AAD) Annual MeetingWAYNE, Pa., March 20, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that an ePoster on the results from its open-label Phase 2a trial of ATI-2138, a potent and selective investigational oral covalent inhibitor of interleukin-2-inducible T cell kinase (ITK) and Janus kinase 3 (JAK3), will be available during the 2026 American Academy of Dermatology (AAD) Annual Meeting in Denver, CO. The poster will include results not previously reported from Aclaris' Phase 2a trial in patients with moderate-to-severe atopic dermatitis (AD). Elect
- PRAclaris Therapeutics Completes Enrollment in Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis- Top Line Results Expected in the Fourth Quarter of 2026 - WAYNE, Pa., March 18, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that it has completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of bosakitug (ATI-045) in patients with moderate-to-severe atopic dermatitis (AD). Top line results are expected in the fourth quarter of 2026. "The strong interest in participating in this Phase 2 trial reflects the urgent need for innovative solutions in atopic dermatitis and the excitement surrou
- SECSEC Form 8-K filed by Aclaris Therapeutics Inc.8-K - Aclaris Therapeutics, Inc. (0001557746) (Filer)
- SECAclaris Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - Aclaris Therapeutics, Inc. (0001557746) (Filer)
- INSIDERChief Financial Officer Balthaser Kevin converted options into 2,375 shares and covered exercise/tax liability with 677 shares, increasing direct ownership by 0.91% to 187,453 units (SEC Form 4)4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)
ACRS FAQ
7 questionsWhat does Aclaris Therapeutics Inc. do?
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel, small molecule therapeutics to address the needs of patients with immuno-inflammatory diseases. The company has a multi-stage portfolio of drug candidates powered by a research and development engine exploring protein kinase regulation. Its products pipeline includes ATI-450, an investigational oral, novel, small molecule selective MK2 inhibitor compound, which is being developed as a treatment for moderate to severe rheumatoid arthritis and additional immuno-inflammatory diseases...Where does ACRS stock trade?
Aclaris Therapeutics Inc. (ACRS) is listed on NASDAQ.What sector and industry is ACRS in?
Aclaris Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Aclaris Therapeutics Inc. go public?
Aclaris Therapeutics Inc. (ACRS) completed its IPO in 2015.What are analysts saying about ACRS?
Aclaris Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Guggenheim: Buy with a $1200.00 price target on 2026-05-05. Recent price targets range from $600.00 to $2000.00.What companies are similar to ACRS?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare ACRS side-by-side with any of them on Quantisnow.How can I track ACRS on Quantisnow?
Quantisnow aggregates Aclaris Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ACRS to receive live email and push alerts on every new disclosure.